BioAge Labs, Inc.
BIOANasdaq
$22.81
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↑ +392.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$969.0M
Enterprise Value
$586.9M
P/E
—
P/S
93.9
P/B
2.6
EV/EBITDA
—
PEG
—
FCF Yield
-9.2%
Dividend Yield
—
Revenue (TTM)
$10.3M
Net Income (TTM)
-$89.9M
Free Cash Flow (TTM)
-$88.6M
Gross Margin
—
Operating Margin
-985.9%
Net Margin
-871.7%
ROE
-23.7%
ROIC
—
Debt / Equity
0.0
Net Cash
$382.0M
Return 1Y
+375.2%
Company profile
We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.
- CEO
- Kristen Fortney
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- California
- Website
- bioagelabs.com
Management & directors
- Barton ShanePrincipal Accounting Officer
- Goldstein Dov A MdChief Financial Officer
- Rubin Paul DChief Medical Officer
- Fortney KristenChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
BIOA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.8M↑ +91.0%
Diluted EPS-$0.52↑ +44.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $0.00 | $9.0M |
| Gross profit | — | — | — |
| Operating income | -$48.4M | -$78.2M | -$92.8M |
| Net income | -$63.9M | -$71.1M | -$80.6M |
| Diluted EPS | -$38.17 | -$6.63 | -$2.24 |
| Operating cash flow | -$37.4M | -$51.5M | -$81.6M |
| Free cash flow | -$37.5M | -$51.9M | -$82.3M |
| Gross margin | — | — | — |
| Operating margin | — | — | -1031.5% |
| Net margin | — | — | -896.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $1.5M | $2.4M | $2.1M | $3.1M | $2.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.3M | -$24.8M | -$25.4M | -$16.4M | -$24.8M | -$23.1M | -$28.4M | -$25.4M |
| Net income | -$13.6M | -$23.4M | -$21.1M | -$12.9M | -$21.6M | -$20.2M | -$25.9M | -$22.3M |
| Diluted EPS | -$7.94 | -$6.70 | $15.77 | -$0.36 | -$0.60 | -$0.56 | -$0.72 | -$0.52 |
| Operating cash flow | -$15.8M | -$14.9M | -$5.1M | -$17.4M | -$20.0M | -$16.0M | -$28.3M | -$24.0M |
| Free cash flow | -$15.8M | -$15.2M | -$5.2M | -$17.8M | -$20.1M | -$16.1M | -$28.4M | -$24.1M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -1133.4% | -1027.0% | -1126.6% | -923.4% | -915.4% |
| Net margin | — | — | — | -891.0% | -894.0% | -982.0% | -842.9% | -802.8% |
Company news
Jul 14, 2026
- 6d agoMore than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026finance.yahoo.com
- 6d agoHitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reductionfinance.yahoo.com
Jun 25, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | Barton Shane· Principal Accounting Officer | Sale | 20,216 | $25.19 | $509,176.35 | filing |
| 2026-06-30 | Barton Shane· Principal Accounting Officer | Option exercise | 4,290 | $10.85 | $46,546.50 | filing |
| 2026-06-30 | Barton Shane· Principal Accounting Officer | Option exercise | 7,861 | $4.38 | $34,431.18 | filing |
| 2026-06-30 | Barton Shane· Principal Accounting Officer | Option exercise | 4,000 | $8.39 | $33,560.00 | filing |
| 2026-06-30 | Barton Shane· Principal Accounting Officer | Option exercise | 4,065 | $4.30 | $17,479.50 | filing |
| 2026-06-29 | Barton Shane· Principal Accounting Officer | Sale | 42,350 | $25.21 | $1.1M | filing |
| 2026-06-29 | Barton Shane· Principal Accounting Officer | Option exercise | 9,301 | $10.85 | $100,915.85 | filing |
| 2026-06-29 | Barton Shane· Principal Accounting Officer | Option exercise | 14,198 | $4.38 | $62,187.24 | filing |
| 2026-06-29 | Barton Shane· Principal Accounting Officer | Option exercise | 7,261 | $8.39 | $60,919.79 | filing |
| 2026-06-29 | Barton Shane· Principal Accounting Officer | Option exercise | 8,958 | $4.30 | $38,519.40 | filing |
| 2026-04-23 | GOLDSTEIN DOV A MD· Chief Financial Officer | Option exercise | 3,542 | $4.38 | $15,513.96 | filing |
| 2026-04-01 | RUBIN PAUL D· Chief Medical Officer | Sale | 8,820 | $17.81 | $157,084.20 | filing |
| 2026-04-01 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 5,437 | $4.11 | $22,346.07 | filing |
| 2026-04-01 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 3,383 | $6.57 | $22,226.31 | filing |
| 2026-03-02 | RUBIN PAUL D· Chief Medical Officer | Sale | 7,433 | $20.30 | $150,889.90 | filing |
| 2026-03-02 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 5,433 | $4.11 | $22,329.63 | filing |
| 2026-03-02 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 2,000 | $6.57 | $13,140.00 | filing |
| 2026-03-01 | GOLDSTEIN DOV A MD· Chief Financial Officer | Option exercise | 3,542 | $4.38 | $15,513.96 | filing |
| 2026-02-02 | RUBIN PAUL D· Chief Medical Officer | Sale | 7,433 | $18.75 | $139,368.75 | filing |
| 2026-02-02 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 5,433 | $4.11 | $22,329.63 | filing |
| 2026-02-02 | RUBIN PAUL D· Chief Medical Officer | Option exercise | 2,000 | $6.57 | $13,140.00 | filing |
| 2026-02-01 | GOLDSTEIN DOV A MD· Chief Financial Officer | Option exercise | 3,541 | $4.38 | $15,509.58 | filing |
| 2026-01-16 | GOLDSTEIN DOV A MD· Chief Financial Officer | Option exercise | 3,542 | $4.38 | $15,513.96 | filing |
| 2026-01-13 | Fortney Kristen· Chief Executive Officer | Sale | 233,107 | $18.12 | $4.2M | filing |
| 2026-01-13 | GOLDSTEIN DOV A MD· Chief Financial Officer | Sale | 11,663 | $20.54 | $239,548.69 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.